AC Immune Advances NLRP3 Inhibitor ACI-19764 in Phase 1
LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...
Phase 1
Advertisement
Enveda Reports Positive Phase 1 Results for ENV-308
BOULDER, Colo., August 18, 2026 Enveda announced positive Phase 1 results for ENV-308, an investigational oral medicine designed from...
Enveric Biosciences Advances EB-003 Toward Phase 1
CAMBRIDGE, Mass., Aug. 14, 2026 Enveric Biosciences reported continued progress in the preclinical development of EB-003, its lead next-generation...
Cue Biopharma Advances CUE-221 Toward Phase 2 Data
BOSTON, Aug. 14, 2026 Cue Biopharma, Inc. reported continued progress across its clinical-stage pipeline, highlighted by the recent Investigational...
Akari Therapeutics and Whitehawk Expand Dual-Payload ADC Strategy
Tampa, Florida and London, United Kingdom — August 13, 2026 Akari Therapeutics, Plc reported progress on its lead antibody-drug...
Advertisements
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Aligos Therapeutics Starts Phase 1 Study of ALG-170675
SOUTH SAN FRANCISCO, Calif., August 12, 2026 Aligos Therapeutics, Inc. announced that its partner Xiamen Amoytop Biotech Co., Ltd....
Intelligent Bio Solutions Completes Clinical Study for FDA 510(k) Submission
NEW YORK, August 11, 2026 Intelligent Bio Solutions Inc. announced the completion of its multi-site Method Comparison Study for...
SNIPR Advances SNIPR001 With Compassionate-Use Clinical Evidence
COPENHAGEN, Denmark, August 12, 2026 SNIPR announced new clinical evidence supporting the translational potential of SNIPR001, its engineered CRISPR-enhanced...
Telix Publishes ProstACT SELECT Study on TLX591-Tx
Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...
Advertisement
